Published within
|«
«
|
...
|
5
|
6
|
7
|
8
|
9
|
10
|
11
|
12
|
13
|
...
|
»
»|
| Type |
Product title / description
|
Pub
|
Price |
CommentWire
|
The success of the erectile dysfunction drug Levitra is crucial for Bayer's [BAY.F] short-term future, as the company has little else in the pipeline to provide growth potential. For GSK [GSK.L], although less vital for survival, the success of this drug launch is also of key importance.
Published By Datamonitor
|
20 Aug 2003 |
|
CommentWire
|
Schering-Plough [SGP] faces increasing competition in markets it used to dominate, such as hepatitis C and allergic rhinitis. The company has attempted to reverse this trend by moving into alternative franchises such as oncology. Schering-Plough may seek to complement its organic growth by partnering with a company that has expertise in this area.<BR />
Published By Datamonitor
|
27 Aug 2003 |
|
CommentWire
|
Novartis [NVS] has joined Mylan [MYL] and Schwarz [SRZG.F] in offering a generic version of blockbuster ulcer drug Prilosec in the US. The arrival of Novartis may open the floodgates for multiple generics in the ulcer drug market. Yet for companies launching generics before legal issues are settled, the risks are huge.
Published By Datamonitor
|
27 Aug 2003 |
|
CommentWire
|
Recent evidence has shown that Johnson & Johnson's [JNJ] Topamax promotes weight loss in obese patients with type II diabetes. The drug is currently used to treat epilepsy although it has shown potential for a number of indications in clinical studies. The company hopes to boost Topamax sales further by penetrating a difficult but potentially lucrative market.<BR />
Published By Datamonitor
|
29 Aug 2003 |
|
CommentWire
|
A new study has reported a substantial decrease in pediatric antibiotic prescriptions between 1996 and 2000. The development shows the success of a wider campaign to reduce overuse of antibiotics - a serious problem that contributes to the development of disease-resistant forms of common bacteria.
Published By Datamonitor
|
04 Sep 2003 |
|
CommentWire
|
GSK's [GSK.L] Ariflo has failed to demonstrate effectiveness in Chronic Obstructive Pulmonary Disease (COPD). Meanwhile, GSK's antidepressant blockbuster Paxil is under threat from generic competition, which will inevitably reduce its market share. Efforts to strengthen the brand will not offset the sales loss.
Published By Datamonitor
|
11 Sep 2003 |
|
CommentWire
|
Procter & Gamble's [PG] launch of Prilosec OTC will have wide-ranging effects on the market for heartburn and ulcer drugs. The availability of an OTC alternative is leading US insurance companies to restrict access to competing prescription drugs. Although generic OTC omeprazole will not be available for several years, PPI companies must find successor products to protect their franchises.
Published By Datamonitor
|
22 Sep 2003 |
|
CommentWire
|
Researchers at the Memorial Sloan-Kettering Cancer Center in the US have reported promising results for a pancreatic cancer vaccine developed using proteins from the patient's own tumor. Although preliminary results appear encouraging, it will be some time before patients can gain access to the drug.
Published By Datamonitor
|
23 Sep 2003 |
|
CommentWire
|
The FDA has requested the submission of Novartis' [NVS] TARGET study report as well as additional clinical data for COX-II inhibitor Prexige. Delayed entry into the already saturated COX-II inhibitor market is bad news for the Swiss company, which hopes to capture market share from leaders Pfizer [PFZ.L] and Merck & Co [MRK].
Published By Datamonitor
|
29 Sep 2003 |
|
CommentWire
|
The approval of Pfizer's [PFE] Inspra (eplerenone) for post-MI heart failure patients, based on the EPHESUS trial results, should be sufficient for use of the drug to exceed that of its less well tolerated predecessor, spironolactone. With marketing support from Pfizer, Inspra is all set for blockbuster status.
Published By Datamonitor
|
13 Oct 2003 |
|
|«
«
|
...
|
5
|
6
|
7
|
8
|
9
|
10
|
11
|
12
|
13
|
...
|
»
»|
No help is available.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Business Insight reports are an objective source of data, analysis and market insight
Insight for technology vendors into customer trends and pain points from key business decision makers.
Butler Group's thought leadership, opinion, with end user case studies and product profiles for key vendors.
Butler Group's vendor ranking and assessment model groups vendors into Outperform, Perform, and Under-perform categories.
Butler Group's thought leadership, opinion, and best practice with technology audits, product comparisons and rankings.
Opinion and market commentary from Datamonitor's industry experts.
Company profiles deliver detailed insight into how companies are organized and function with SWOT analysis.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Opinion and market commentary from Datamonitor's industry experts.
Track industry events, markets, products, customers, prospects, competitors and partners
Country profiles presenting easy-to-digest summaries and standardized data.
Databooks use charts and tables to provide a data-centric view of a particular market or category
Opinion and market commentary from Datamonitor's industry experts.
Comprehensive category data, including market value, volume, segmentation and share, with analysis.
Industry profiles provide standardized market data (including size & segmentation) and competitive analysis.
Market sizing and forecast data for a market or sector delivered in spreadsheet format.
Track industry events, markets, products, customers, prospects, competitors and partners
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Opinion and market commentary from Datamonitor's industry experts.
Insight for technology vendors into customer trends and pain points from key business decision makers.
Business information covering a specific market or issue.